S.M. Gold (542034)
Asset PlayScore breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹17.03 |
| Market Cap | ₹17.09 Cr |
| P/E Ratio | 20.55 |
| ROCE | 3.33% |
| ROE | 3.93% |
| Dividend Yield | 0% |
| Profit Growth | 50% |
| Debt/Equity | — |
| Sales Growth | 67.32% |
| 52-Week Range | ₹10.66 — ₹20.7 |
| Sector | Consumer Durables |
| Book Value | ₹19.19 |
Strengths
- Trading at ₹17.03 versus book value ₹19.19, an 11% discount to stated book
- Sales growth of 67.32% shows meaningful revenue expansion
- Profit growth of 50.00% and PEG of 0.35 suggest momentum if earnings sustain
- Piotroski F-score of 7/9 indicates relatively sound financial health across profitability, leverage and efficiency metrics
Concerns
- Latest quarter shows ₹53 Cr sales but nearly zero net profit, highlighting extremely thin margins
- ROE of 3.93% and ROCE of 3.33% reflect weak capital efficiency and a limited moat
- Debt/Equity and promoter holding are not available, leaving key governance and risk questions unanswered
- No dividend yield means returns depend entirely on capital appreciation and future business performance
AI Analysis
Let me start with what attracts me: the stock trades at ₹17.03 against a book value of ₹19.19, a P/B of 0.89. Mr. Market is offering this jewellery business at a discount to what the balance sheet says. But cheapness alone is never enough. The business earns a meagre 3.93% ROE and 3.33% ROCE. That tells me there is no extraordinary franchise here; it is a competitive, commodity-like jewellery business where profits are thin. The latest quarter says it all: ₹53 crore of sales but nearly zero net profit. That is a razor-thin margin. The 67.32% sales growth and 50.00% profit growth look exciting, but I am suspicious of the small base and seasonal jewellery demand. A 20.55 P/E on a company earning almost nothing in the latest quarter is not a bargain in earnings terms; it is a bargain only in book value terms. The Piotroski F-score of 7/9 does suggest improving financial health, but with Debt/Equity not disclosed, I cannot assess leverage risk. No dividend means I am asked to wait solely for capital appreciation. This is not the kind of compounder I prefer. Buying slightly below book can provide margin of safety, but only if the assets are truly productive and management is honest. With low returns and zero profit in a recent quarter, I would want plenty of investigation before committing. If the balance sheet stays strong and quarterly earnings recover, there may be an asset-backed turnaround; until then, it is more of an asset play.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer